Example: Heart Attack

Clinical Trials on Atypical Hemolytic Uremic Syndrome

Total 28 results

NCT01194973

Completed

An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Conditions: Atypical Hemolytic-Uremic Syndrome
NCT01193348

Completed

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

Conditions: Atypical Hemolytic-Uremic Syndrome
NCT03303313

Withdrawn

A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome

Conditions: Atypical Hemolytic Uremic Syndrome
NCT01522183

Recruiting

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Conditions: Atypical Hemolytic-Uremic Syndrome
NCT03131219

Active, not recruiting

Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

Conditions: Atypical Hemolytic Uremic Syndrome (aHUS)
NCT02949128

Active, not recruiting

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Conditions: Atypical Hemolytic Uremic Syndrome (aHUS)
NCT00838513

Completed

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)

Conditions: Atypical Hemolytic Uremic Syndrome
NCT01770951

Completed

A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Conditions: Atypical Hemolytic Uremic Syndrome (aHUS)
NCT00930423

Unknown status

Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease

Conditions: Atypical Hemolytic Uraemic Syndrome.
NCT02574403

Completed

Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS

Conditions: Atypical Hemolytic Uremic Syndrome
NCT03205995

Unknown status

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

Conditions: Thrombotic Microangiopathies; Atypical Hemolytic Uremic Syndrome
NCT02464891

Terminated

Complement Inhibition in aHUS Dialysis Patients

Conditions: Atypical Hemolytic Uremic Syndrome
NCT01522170

Terminated

aHUS Observational Long Term Follow-Up

Conditions: Atypical Hemolytic Uremic Syndrome
NCT03999840

Withdrawn

Eculizumab to Cemdisiran Switch in aHUS

Conditions: Atypical Hemolytic Uremic Syndrome
NCT02614898

Terminated

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment

Conditions: Atypical Hemolytic Uremic Syndrome
NCT01757431

Completed

The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Conditions: Atypical Hemolytic Uremic Syndrome (aHUS)
NCT00844545

Completed

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

Conditions: Atypical Hemolytic Uremic Syndrome
NCT00844844

Completed

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS

Conditions: Atypical Hemolytic Uremic Syndrome
NCT00844428

Completed

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS

Conditions: Atypical Hemolytic Uremic Syndrome
NCT03574506

Active, not recruiting

Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series

Conditions: Atypical Hemolytic Uremic Syndrome; Pregnancy
NCT01755429

Completed

To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

Conditions: ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
NCT03518203

Recruiting

Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

Conditions: Thrombotic Microangiopathies; Atypical Hemolytic Uremic Syndrome; Multiple Organ Dysfunction Syndrome
NCT04749810

Recruiting

Observational Study of Elizaria® in aHUS Patients

Conditions: Atypical Hemolytic Uremic Syndrome; aHUS
NCT03829449

Recruiting

rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study

Conditions: Paroxysmal Nocturnal Hemoglobinuria; Atypical Hemolytic Uremic Syndrome
NCT02626663

Withdrawn

The Role of Microparticles as a Biomarker

Conditions: Atypical Hemolytic Uremic Syndrome; Thrombotic Thrombocytopenic Purpura; Microparticles; Microangiopathic Hemolytic Anemia